"The U.S. Food and Drug Administration today approved Procysbi (cysteamine bitartrate) for the management of nephropathic cystinosis in children and adults. Procysbi was granted orphan product designation because it is intended to treat a rare dis"...
In clinical studies, patients have occasionally experienced nausea during PhosLo (calcium acetate tablet) therapy. Hypercalcemia may occur during treatment with PhosLo (calcium acetate tablet) . Mild hypercalcemia (Ca>10.5mg/dL) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcemia (Ca>12mg/dl) is associated with confusion, delirium, stupor and coma. Mild hypercalcemia is easily controlled by reducing the PhosLo (calcium acetate tablet) dose or temporarily discontinuing therapy. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing PhosLo (calcium acetate tablet) therapy. Decreasing dialysate calcium concentration could reduce the incidence and severity of PhosLo (calcium acetate tablet) induced hypercalcemia. The long-term effect of PhosLo (calcium acetate tablet) on the progression of vascular or soft-tissue calcification has not been determined.
Isolated cases of pruritus have been reported which may represent allergic reactions.
Read the Phoslo (calcium acetate tablet) Side Effects Center for a complete guide to possible side effects »
PhosLo (calcium acetate tablet) may decrease the bioavailability of tetracyclines.
Last reviewed on RxList: 5/27/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Phoslo Information
Phoslo - User Reviews
Phoslo User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.